Press release

LFB's « Usine 2020 »
Global production from a plant "made in France"

LFB files construction permits

Les Ulis, 1st July 2016 - The biopharmaceutical group LFB announces the filing of construction permits for its "next generation" plant dedicated to the manufacture of plasma-derived medicinal products, which will be settled in the industrial area "Actiparc" within the urban community of Arras (cities of Baillel-sire-Berthoult and Saint Laurent Blangy).

The challenges of "Usine 2020". The LFB group, a French champion in the field of biological medicines, currently runs four plants in France, among which two are dedicated to the manufacture of plasma-derived medicinal products, in les Ulis and Lille. To ensure its growth and international development, LFB decided to develop its production capacity with a "next generation" plant. "Usine 2020" should allow a three-fold increase in the manufacture of LFB's plasma derivatives in the ten years to come, as well as an optimization of production costs to strengthen the group's competitiveness in a highly technological field and to meet the highest worldwide standards, and then manufacture for the world. This plant was mentioned by French Economy Minister Emmanuel Macron during the parliamentary debates about LFB**, in the course of the review of the "growth and activity" bill, highlighting the growth-promoting aspect of the project.

Key figures of the manufacturing site. The selected site consists of 15 hectares of land with initial use of 9 hectares, and a land reserve of 6 hectares in order to enable future production developments and new production units after 2020. The plant will notably include a manufacturing unit for immunoglobulins, a unit dedicated to fibrinogen, a unit for pharmaceutical formatting for liquid and lyophilized products. The whole project corresponds to an investment of around 300 euromillions.

The choice of Arras. After thorough evaluation of seven potential sites for the plant, in the past two years, LFB chose to locate "Usine 2020" in the industrial area of Actiparc within the Arras urban community, for its adequacy to the current and future needs of the group, along with a Local Urbanism Plan suited to industrial activity. The proximity of the present LFB site in Lille also was a strong argument in the group's decision to choose a site in the Nord-Pas-de-Calais-Picardie region.

*The two other plants are in Alès (LFB Biomanufacturing) , dedicated notably to the manufacture of monoclonal antibodies, and in Les Ulis (CELL*for*CURE), with an industrial platform for the manufacture of cell and gene therapy medicinal products.
** Article 48 aims at allowing "other companies or organizations belonging to the public sector" along with the French State and its public establishments, to enter LFB's capital.

About LFB. *The LFB group (www.lfb.fr) is a biopharmaceutical company that develops, manufactures, and markets medicinal products for the treatment of serious and often rare diseases in the fields of Immunology, Haemostasis, Perinatal, and Intensive Care. The LFB group is the leading manufacturer of plasma-derived medicinal products in France and 6th worldwide, and is also among the leading European companies for the development of new-generation medicinal products or treatments based on biotechnologies.*

The LFB group is pursuing a growth strategy that seeks to extend its international activities and develop innovative therapies. Today, the LFB group currently markets its products in more than 40 countries around the world with a global turnover of € 501,9 million in 2014. www.lfb.fr

Contact LFB S.A
Sandrine Charrières – Executive VP Corporate Communications
Phone: +33 (1) 69 82 72 80
charrieres@lfb.fr

Media contact : Jeanne Bariller
Havas Worldwide
Phone : +33 6.15.51.49.40
jeanne.bariller@havasww.com

Connect with LFB Group on social networks
http://www.twitter.com/LFB_Group

http://www.linkedin.com/company/lfb

http://www.youtube.com/user/LFBGroup